New drug duo aims to stall ovarian Cancer's return
NCT ID NCT05335993
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding oregovomab (an antibody) to niraparib (a daily pill) can better control platinum-sensitive recurrent ovarian cancer. Ten women whose cancer came back after initial chemotherapy will receive both drugs for 12 weeks. The main goal is to see how many patients have their disease shrink or stay stable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oregovomab (a monoclonal antibody) and niraparib (a drug, brand name Zejula)
- What this could lead to
- If it works, this combination could help control recurrent ovarian cancer for longer, delaying the need for more chemotherapy.
- What could go wrong
- This is a very small, early-phase trial with only 10 participants. It may not show benefit, and side effects from the drugs could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF OVARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Stephenson Cancer Center- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a Patient's own immune cells be supercharged to fight ovarian cancer?
- Radioactive antibody targets rare childhood cancer
- New drug cocktail aims to shrink recurrent ovarian tumors
- New model could predict dangerous gut leak after ovarian cancer surgery